Cargando…
Entecavir-associated thrombocytopenia
Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674478/ https://www.ncbi.nlm.nih.gov/pubmed/34823407 http://dx.doi.org/10.1177/20587384211059676 |
_version_ | 1784615663882469376 |
---|---|
author | Yu, Yi Feng, Hao |
author_facet | Yu, Yi Feng, Hao |
author_sort | Yu, Yi |
collection | PubMed |
description | Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*10(9)/L to 3*10(9)/L and was prone to gum bleeding and skin ecchymosis after she received ETV treatment for 88 days. As a treatment option, ETV was replaced by TDF immediately, frequent platelets transfusions and thrombopoietin were applied for several days, daily prednisone of 50 mg was concomitantly taken, and then platelet count improved after 10 days. She was diagnosed with entecavir-associated thrombocytopenia after analysis of the temporal relationship and exclusion of other causes of thrombocytopenia by blood and bone marrow examinations. Our case suggested that the platelet count should be monitored regularly in patients during ETV treatment, and it may be a feasible option to choose TDF to maintain antiviral treatment when entecavir-associated thrombocytopenia occurs. |
format | Online Article Text |
id | pubmed-8674478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-86744782021-12-17 Entecavir-associated thrombocytopenia Yu, Yi Feng, Hao Int J Immunopathol Pharmacol Case Report Entecavir (ETV) is widely used in the treatment of hepatitis B, but there are only a few reports about entecavir-associated thrombocytopenia, and it is considered as an immediate response and inappropriate to continue the treatment with other nucleoside analogues. Now, we report the third case, and this case was delayed response and we switched to treatment with tenofovir (TDF). There was a 66-year-old female who was infected with hepatitis B virus (HBV). Her platelet count decreased from 111*10(9)/L to 3*10(9)/L and was prone to gum bleeding and skin ecchymosis after she received ETV treatment for 88 days. As a treatment option, ETV was replaced by TDF immediately, frequent platelets transfusions and thrombopoietin were applied for several days, daily prednisone of 50 mg was concomitantly taken, and then platelet count improved after 10 days. She was diagnosed with entecavir-associated thrombocytopenia after analysis of the temporal relationship and exclusion of other causes of thrombocytopenia by blood and bone marrow examinations. Our case suggested that the platelet count should be monitored regularly in patients during ETV treatment, and it may be a feasible option to choose TDF to maintain antiviral treatment when entecavir-associated thrombocytopenia occurs. SAGE Publications 2021-11-25 /pmc/articles/PMC8674478/ /pubmed/34823407 http://dx.doi.org/10.1177/20587384211059676 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Yu, Yi Feng, Hao Entecavir-associated thrombocytopenia |
title | Entecavir-associated thrombocytopenia |
title_full | Entecavir-associated thrombocytopenia |
title_fullStr | Entecavir-associated thrombocytopenia |
title_full_unstemmed | Entecavir-associated thrombocytopenia |
title_short | Entecavir-associated thrombocytopenia |
title_sort | entecavir-associated thrombocytopenia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674478/ https://www.ncbi.nlm.nih.gov/pubmed/34823407 http://dx.doi.org/10.1177/20587384211059676 |
work_keys_str_mv | AT yuyi entecavirassociatedthrombocytopenia AT fenghao entecavirassociatedthrombocytopenia |